InvestSMART

Paradigm Biopharmaceuticals Limited (ASX: PAR) - Announcements

- Current share price for PAR : $0.205

ASX company news and announcements for Paradigm Biopharmaceuticals Limited (PAR) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Paradigm Biopharmaceuticals Limited (PAR) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Paradigm Biopharmaceuticals Limited (PAR), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Paradigm Biopharmaceuticals Limited (PAR)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$124 Paradigm AGM Presentation 29 Nov 2022 11:36AM $1.430 $0.205 fallen by 85.66%
$124 Notice of Annual General Meeting-Withdrawal of Resolutions 29 Nov 2022 8:27AM $1.445 $0.205 fallen by 85.81%
$124 Application for quotation of securities - PAR 25 Nov 2022 1:40PM $1.475 $0.205 fallen by 86.10%
$124 Cancel - Application for quotation of securities - PAR 25 Nov 2022 12:16PM $1.450 $0.205 fallen by 85.86%
$124 Application for quotation of securities - PAR 23 Nov 2022 4:39PM $1.510 $0.205 fallen by 86.42%
$124 Paradigm CEO steps down & Appointment of MD 22 Nov 2022 9:21AM $1.700 $0.205 fallen by 87.94%
$124 Paradigm Receives $7.4m R&D Tax Incentive Refund 18 Nov 2022 2:06PM $1.530 $0.205 fallen by 86.60%
$124 Notice of release of escrowed securities 14 Nov 2022 4:51PM $1.595 $0.205 fallen by 87.15%
$124 MPS-VI Program Accepted for Presentation at WorldSymposium 11 Nov 2022 9:23AM $1.580 $0.205 fallen by 87.03%
$124 Bell Potter Virtual Healthcare Conference presentation 9 Nov 2022 9:14AM $1.650 $0.205 fallen by 87.58%
$124 Quarterly Activities/Appendix 4C Cash Flow Report 31 Oct 2022 7:57AM $1.340 $0.205 fallen by 84.70%
$124 Notice of Annual General Meeting/Proxy Form 28 Oct 2022 1:06PM $1.420 $0.205 fallen by 85.56%
$124 Paradigm Doses First UK Participant in Phase 3 Trial 26 Oct 2022 9:35AM $1.280 $0.205 fallen by 83.98%
$124 PAR Reports Successful Primary Endpoint in Phase 2 Trial 4 Oct 2022 9:13AM $1.260 $0.205 fallen by 83.73%
$124 Trading Halt 30 Sep 2022 8:40AM $1.260 $0.205 fallen by 83.73%
$124 Successful MPSVI Safety Review and PARA OA 008 Update 26 Sep 2022 9:11AM $1.270 $0.205 fallen by 83.86%
$124 Date of AGM & Closing Date for Director Nominations 23 Sep 2022 4:56PM $1.270 $0.205 fallen by 83.86%
$124 Change in substantial holding 19 Sep 2022 3:39PM $1.200 $0.205 fallen by 82.92%
$124 Change of Director's Interest Notice 19 Sep 2022 3:38PM $1.200 $0.205 fallen by 82.92%
$124 Application for quotation of securities - PAR 14 Sep 2022 5:15PM $1.280 $0.205 fallen by 83.98%
$124 NOTICE OF RELEASE OF ESCROWED SECURITIES 14 Sep 2022 4:30PM $1.280 $0.205 fallen by 83.98%
$124 Application for quotation of securities - PAR 14 Sep 2022 10:59AM $1.275 $0.205 fallen by 83.92%
$124 Successful Completion of Entitlement Offer 13 Sep 2022 8:21AM $1.290 $0.205 fallen by 84.11%
$124 Paradigm Appoints Interim Company Secretary 30 Aug 2022 8:43AM $1.270 $0.205 fallen by 83.86%
$124 Appendix 4G and 2022 Corporate Governance Statement 26 Aug 2022 9:55AM $1.280 $0.205 fallen by 83.98%

276 - 300 of 724 results

Page 12 of 29

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.